Sign In
Buy HRTX
$0.496
-0.0012 (-0.241%)
At Close: Jul 31, 2026
Heron Therapeutics (HRTX) Received its Third Buy in a Row
03:58pm, Monday, 02'nd Mar 2020
After Cowen & Co. and Cantor Fitzgerald gave Heron Therapeutics (NASDAQ: HRTX) a Buy rating last month, the company received another Buy, this time
Heron Therapeutics (HRTX) Received its Third Buy in a Row
03:57pm, Monday, 02'nd Mar 2020
After Cowen & Co. and Cantor Fitzgerald gave Heron Therapeutics (NASDAQ: HRTX) a Buy rating last month, the company received
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
02:05pm, Monday, 02'nd Mar 2020
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -12.07% and 0.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics: 4Q Earnings Snapshot
01:01pm, Monday, 02'nd Mar 2020
SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Monday reported a loss of $57.9 million in its fourth quarter. The San Diego-based company said it had a loss of 65 cents per share. The results miss
Heron Therapeutics: 4Q Earnings Snapshot
12:59pm, Monday, 02'nd Mar 2020
SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Monday reported a loss of $57.9 million in its fourth quarter.
The San Diego-based company said it had a loss of 65 cents per share.
The results miss
Heron Therapeutics Q4 EPS $(0.65) Down From $(0.63) YoY, Sales $35.083M Up From $28.844M YoY
12:33pm, Monday, 02'nd Mar 2020
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan
First Trust Advisors LP Makes New Investment in Heron Therapeutics Inc (NASDAQ:HRTX)
11:22am, Monday, 02'nd Mar 2020
First Trust Advisors LP purchased a new position in Heron Therapeutics Inc (NASDAQ:HRTX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
12:00am, Monday, 02'nd Mar 2020Analysts: 3 Beaten-Down Stocks to Buy on Weakness
06:19pm, Thursday, 27'th Feb 2020
A stock can experience a pullback for a variety of reasons, be it disappointing quarterly results, the impact of internal politics, or the effect of the coronavirus on the economy. Yet, traditionally,
Analysts: 3 "Strong Buy" Stocks to Buy on Weakness
06:08pm, Thursday, 27'th Feb 2020
A stock can experience a pullback for a variety of reasons, be it disappointing quarterly results, the impact of internal politics, or the effect of the
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
01:42pm, Thursday, 27'th Feb 2020
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
01:42pm, Thursday, 27'th Feb 2020
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio
09:42pm, Wednesday, 26'th Feb 2020
The biotech sector was in focus with pipeline updates from a few small biotech companies.
Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio
09:42pm, Wednesday, 26'th Feb 2020
The biotech sector was in focus with pipeline updates from a few small biotech companies.
